-transparent.png){kind=logo}
Essentials Protein Z (PZ) catalyzes PZ-dependent proteinase inhibitor (ZPI) inactivation of factor (F)Xa. Gene-deletion of PZ or ZPI improves coagulation in hemophilia (FVIII knockout) mice. A PZ blocking antibody enhances thrombin generation in human hemophilia plasma. Suppression of the PZ/ZPI pathway may ameliorate the phenotype of severe hemophilia. SUMMARY: Background Hemostasis requires a balance between procoagulant and anticoagulant factors. Hemophiliacs bleed because of a procoagulant deficiency. Targeted reduction in the activity of endogenous anticoagulant pathways is currently being investigated as a means of improving hemostasis in hemophilia. Protein Z (PZ) is a cofactor that serves as a catalyst for PZ-dependent protease inhibitor (ZPI) inactivation of activated factor X at phospholipid surfaces. Objectives To evaluate the effects of PZ or ZPI gene deletion in hemophilic mice, and of blocking PZ in human hemophilic plasma. Methods A tail vein rebleeding assay (TVRB) was developed on the basis of the serial disruption of clots forming over a period of 15 min following tail vein laceration in an anesthetized mouse. Wild-type (WT)/FVIII knockout FVIIIKO, PZ knockout PZKO/FVIIIKO and ZPI knockout ZPIKO/FVIIIKO mice were evaluated in this model, and their plasmas were tested in thrombin generation assays. A mAb against PZ was evaluated in human hemophilic plasma thrombin generation assays. Results The numbers of clot disruptions (mean ± standard error of the mean) in the TVRB were: 4.0 ± 0.9 for WT/FVIIIKO mice; 23.8 ± 1.1 for WT/FVIIIKO mice supplemented with 100% FVIII; 15.2 ± 1.1 for PZKO/FVIIIKO mice; and 14.7 ± 1.2 for ZPIKO/FVIIIKO mice. Thrombin generation in PZKO/FVIIIKO and ZPIKO/FVIIIKO mouse plasmas was similar to that in FVIIIKO plasma supplemented with ~ 15% recombinant FVIII. A mAb against PZ added to human hemophilic plasma enhanced thrombin generation to an extent similar to the addition of ~ 15% FVIII. Conclusions Blockade of the PZ/ZPI system may be sufficient to ameliorate the phenotype of severe hemophilia.
T J Girard, and
N M Lasky, and
K Grunz, and
G J Broze
January 2012,
ISRN hematology,
T J Girard, and
N M Lasky, and
K Grunz, and
G J Broze
October 2008,
The Journal of biological chemistry,
T J Girard, and
N M Lasky, and
K Grunz, and
G J Broze
June 2014,
Cardiovascular therapeutics,
T J Girard, and
N M Lasky, and
K Grunz, and
G J Broze
October 2011,
Nature biotechnology,
T J Girard, and
N M Lasky, and
K Grunz, and
G J Broze
July 2001,
Thrombosis and haemostasis,
T J Girard, and
N M Lasky, and
K Grunz, and
G J Broze
June 2001,
Current topics in medicinal chemistry,
T J Girard, and
N M Lasky, and
K Grunz, and
G J Broze
September 1981,
Thrombosis research,
T J Girard, and
N M Lasky, and
K Grunz, and
G J Broze
February 1989,
Blood,
T J Girard, and
N M Lasky, and
K Grunz, and
G J Broze
February 2002,
Blood,
T J Girard, and
N M Lasky, and
K Grunz, and
G J Broze
November 1997,
Circulation research,
